Phase 2 Multiple Sclerosis Trial, By Invitation NCT06223074 Sponsor: Universidad Nacional Autonoma de Mexico Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, By Invitation

NCT06223074
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 18 and 65 years.
  • People who have been diagnosed with relapsing-remitting multiple sclerosis (RRMS), with their diagnosis being between 3 months and 10 years ago.
  • People whose level of disability, as measured by a standard MS scale called the EDSS, falls between 1 and 6 (a score of 6 includes people who need some support on one side to walk).
  • People who have no medical reason preventing them from receiving the study medication (methylprednisolone, or MP).
  • People who have read and signed a consent form agreeing to take part in the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have taken anti-inflammatory steroid medications within the last 3 days.
  • People who currently have an active bacterial, viral, or fungal infection, or who are currently being treated for one.
  • People who have high blood pressure.
  • People who have diabetes.
  • People who have an underactive or overactive thyroid.
  • People who have glaucoma (a condition affecting eye pressure).
  • People who have or have had a tumour or cancer.
  • People who have been diagnosed with a serious ongoing condition affecting the heart, lungs, liver, hormone systems, digestive system, or similar body systems.
  • People who are pregnant or where pregnancy is suspected, based on blood or urine testing.
  • People who are currently breastfeeding.
  • People who have previously not responded to steroid medications called glucocorticoids.
  • People who have previously had a severe reaction to glucocorticoid medications.
  • People who have a history of reduced or lost sense of smell.
  • People who currently have an active sinus infection.
  • People who have allergic rhinitis (such as hay fever or ongoing nasal allergies).
  • People who currently have an upper respiratory tract infection (such as a cold or similar illness affecting the nose and throat).
  • People who have a deviated septum (where the wall inside the nose is shifted to one side).
  • People who have previously had surgery on their nose.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Sponsor
Universidad Nacional Autonoma de Mexico
Registry
ClinicalTrials.gov
Start date
9 January 2023
Est. completion
25 February 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Patients' score on the Expanded Disability Status Scale (EDSS) before and after treatment to assess clinical efficacy of treatments

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov